BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Authors:
Top Cited Papers
- 22 May 2024
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (10) , 1304-1314
Abstract
Objectives This study aims to evaluate the safety and efficacy of BCMA-CD19 compound chimeric antigen receptor T cells (cCAR) to dual reset the humoral and B cell immune system in patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN). Methods This is a single-arm open-label multicentre phase 1 study of BCMA and CD19-directed cCAR in patients suffering from SLE/LN with autoantibodies produced by B cells and plasma/long-lived plasma cells. In this clinical trial, we sequentially assigned biopsy-confirmed (classes III–V) LN patients to receive 3×106 cCAR cells/kg postcessation of all SLE medications and conditioning. The primary endpoint of safety and toxicity was assessed. Complete immune reset was indicated by B cell receptor (BCR) deep sequencing and flow cytometry analysis. Patient 11 (P11) had insufficient lymphocyte counts and was underdosed as compassionate use. Results P1 and P2 achieved symptom and medication-free remission (MFR) from SLE and complete remission from lymphoma. P3–P13 (excluding P11) received an initial dose of 3×106 cCAR cells /kg and were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR and the complement returned to normal levels. These patients achieved symptom and MFR with post-cCAR follow-up to 46 months. Complete recovery of B cells was seen in 2–6 months post-cCAR. Mean SLE Disease Activity Index 2000 reduced from 10.6 (baseline) to 2.7 (3 months), and renal function significantly improved in 10 LN patients ≤90 days post-cCAR. cCAR T therapy was well tolerant with mild cytokine-release syndrome. Conclusions Data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in patients with SLE.Keywords
Funding Information
- the Natural Science Foundation of Guangdong Province (2021A1515011320)
- Major scientific research project of basic and applied basic research in Guangdong Province (B2022151523007)
This publication has 31 references indexed in Scilit:
- Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapyMolecular Therapy - Methods & Clinical Development, 2023
- Expert Perspective: An Approach to Refractory Lupus NephritisArthritis & Rheumatology, 2022
- Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseasesJournal of Translational Autoimmunity, 2022
- Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T CellsStem Cell Reviews and Reports, 2021
- Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis PatientsNeurology and Therapy, 2020
- Does Resetting the Immune System Fix Multiple Sclerosis?Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2019
- Systemic lupus erythematosus: Diagnosis and clinical managementJournal of Autoimmunity, 2019
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialThe Lancet Oncology, 2018
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activityLeukemia, 2017
- Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseasesCurrent Research in Translational Medicine, 2016